Fulvestrant (Faslodex®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer:: a single-center experience.

被引：0
|
作者：
Franco, S
Perez, A
Tan-Chiu, E
Frankel, C
Vogel, C
机构：
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [21] Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+metastatic breast cancer patients: A single-center experience.
    Papaldo, P.
    Metro, G.
    Felici, A.
    Russillo, M.
    Pellegrini, D.
    Fabi, A.
    Ferretti, G.
    Introna, M.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] FULVESTRANT ('FASLODEX'): A NEW OPTION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
    Kleeberg, Ulrich R.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3537 - 3537
  • [23] Combination of liposomal doxorubicine plus gemcitabine in heavily pretreated metastatic breast cancer patients: A single center experience.
    Pablo Fusco, Juan
    Martin Romano, Patricia
    Castanon Alvarez, Eduardo
    Ceniceros, Lucia
    Legaspi, Jairo
    Espinos, Jaime
    Gil-Bazo, Ignacio
    Fernandez-Hidalgo, Oscar
    Aramendia, Jose M.
    Santisteban, Marta
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: A single-centre experience
    Steger, GG
    Bartsch, R
    Wenzel, C
    Pluschni, U
    Hussian, D
    Sevelda, U
    Locker, GJ
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (17) : 2655 - 2661
  • [25] Fulvestrant in heavily pretreated patients with advanced breast cancer:: experience from a Named Patient Programme in Switzerland
    Hawle, H.
    Thuerlimann, B.
    Pagani, O.
    Buser, K.
    Bonnefoi, H.
    Forni, M.
    Aapro, M.
    Mach, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
  • [26] Fulvestrant in the treatment of postmenopausal women with advanced breast cancer
    Gradishar, W
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (03) : 445 - 453
  • [27] Eribulin and carboplatin in heavily pretreated patients with metastatic breast cancer: A single institution experience.
    Romano, Patricia Martin
    Baraibar, Iosune
    Fernandez-Hidalgo, Oscar
    Santisteban, Marta
    Espinos, Jaime
    Salas, Diego
    Sala, Pablo
    Gardeazabal, Itziar
    Zubiri Oteiza, Leyre
    Aramendia, Jose M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [28] Early use of fulvestrant for the treatment of postmenopausal women with advanced breast cancer - the Nottingham experience
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 162 - 162
  • [29] Postmenopausal women with advanced breast cancer who have progressed after fulvestrant (Faslodex®) remain sensitive to other endocrine agents
    Vergote, I
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S96 - S96
  • [30] Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer
    Robertson, JFR
    Harrison, MP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 346 - 348
12345